title: De novo peptide design and experimental validation of histone methyltransferase inhibitors.
abstract: Histones are small proteins critical to the efficient packaging of DNA in the nucleus. DNA–protein complexes, known as nucleosomes, are formed when the DNA winds itself around the surface of the histones. The methylation of histone residues by enhancer of zeste homolog 2 (EZH2) maintains gene repression over successive cell generations. Overexpression of EZH2 can silence important tumor suppressor genes leading to increased invasiveness of many types of cancers. This makes the inhibition of EZH2 an important target in the development of cancer therapeutics. We employed a three-stage computational de novo peptide design method to design inhibitory peptides of EZH2. The method consists of a sequence selection stage and two validation stages for fold specificity and approximate binding affinity. The sequence selection stage consists of an integer linear optimization model that was solved to produce a rank-ordered list of amino acid sequences with increased stability in the bound peptide-EZH2 structure. These sequences were validated through the calculation of the fold specificity and approximate binding affinity of the designed peptides. Here we report the discovery of novel EZH2 inhibitory peptides using the de novo peptide design method. The computationally discovered peptides were experimentally validated in vitro using dose titrations and mechanism of action enzymatic assays. The peptide with the highest in vitro response, SQ037, was validated in nucleo using quantitative mass spectrometry-based proteomics. This peptide had an IC50 of 13.5 mM, demonstrated greater potency as an inhibitor when compared to the native and K27A mutant control peptides, and demonstrated competitive inhibition versus the peptide substrate. Additionally, this peptide demonstrated high specificity to the EZH2 target in comparison to other histone methyltransferases. The validated peptides are the first computationally designed peptides that directly inhibit EZH2. These inhibitors should prove useful for further chromatin biology investigations.
authors.forename: James
authors.initials: J
authors.lastname: Smadbeck
authors.forename: Meghan B
authors.initials: MB
authors.lastname: Peterson
authors.forename: Barry M
authors.initials: BM
authors.lastname: Zee
authors.forename: Shivani
authors.initials: S
authors.lastname: Garapaty
authors.forename: Aashna
authors.initials: A
authors.lastname: Mago
authors.forename: Christina
authors.initials: C
authors.lastname: Lee
authors.forename: Athanassios
authors.initials: A
authors.lastname: Giannis
authors.forename: Patrick
authors.initials: P
authors.lastname: Trojer
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Garcia
authors.forename: Christodoulos A
authors.initials: CA
authors.lastname: Floudas
references.citation: PLoS One. 2014 Feb 28;9(2):e90095
references.pmid: 24587223